Is Dutasteride a Therapeutic Alternative for Amyotrophic Lateral Sclerosis?

August 2022 in “ Biomedicines ”

Belén Proaño, Julia Casani-Cubel, María Benlloch, Ana Rodriguez-Mateos, Esther Navarro-Illana, Jose María Lajara-Romance, José Enrique de la Rubia Ortí

Dutasteride androgenic alopecia 5α-reductase progesterone testosterone Avodart

Studysummary This review assesses the potential of dutasteride as a promising treatment for ALS due to its reported neuroprotective, antioxidant, and anti-inflammatory effects, but emphasizes that clinical studies are needed for confirmation.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

research LINCS Dataset-Based Repositioning of Dutasteride as an Anti-Neuroinflammation Agent

6 citations , October 2021 in “Brain Sciences”

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

41 citations , February 2021 in “Cureus”

This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.

A Microscopy-Based Small Molecule Screen in Primary Neurons Reveals Neuroprotective Properties of the FDA-Approved Anti-Viral Drug Elvitegravir

research A Microscopy-Based Small Molecule Screen in Primary Neurons Reveals Neuroprotective Properties of the FDA-Approved Anti-Viral Drug Elvitegravir

3 citations , September 2020 in “Molecular Brain”

This study reports that Elvitegravir, a drug currently approved for other uses, shows potential as a neuro- and mitoprotective agent by attenuating mitochondrial damage caused by NMDA receptors in primary mouse cortical neurons.

research Effect of the 5α-Reductase Enzyme Inhibitor Dutasteride in the Brain of Intact and Parkinsonian Mice

16 citations , October 2017 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology”

This study found that dutasteride may offer neuroprotection in early-stage Parkinson's disease by preventing loss of striatal dopamine and altering steroid levels in MPTP-lesioned mice.

research Adverse Effects and Safety of 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review

32 citations , July 2016 in “PubMed”

This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.

research The 5α-Reductase Inhibitor Dutasteride but Not Finasteride Protects Dopamine Neurons in the MPTP Mouse Model of Parkinson’s Disease

27 citations , May 2015 in “Neuropharmacology”

This study found that Dutasteride, a 5α-reductase inhibitor, demonstrated neuroprotective effects by preventing the MPTP-induced decline of dopaminergic markers in a Parkinson's disease mouse model.

research New Steps Forward in the Neuroactive Steroid Field

31 citations , March 2015 in “The Journal of Steroid Biochemistry and Molecular Biology”

This review discusses the complexity of neuroactive steroid therapies for neuroprotection and reports no new clinical findings, suggesting potential unexpected effects in the brain compared to systemic levels.

research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α-Reductase Inhibitor

58 citations , March 2006 in “Current topics in medicinal chemistry”

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

research Androgen-Induced Neurite Outgrowth Is Mediated By Neuritin In Motor Neurons

104 citations , December 2004 in “Journal of Neurochemistry”

This study found that androgens, specifically DHT, induced neurite outgrowth in motor neurons by up-regulating the neuritin protein, with testosterone being less effective.

research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

408 citations , May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

research Steroid 5α-Reductases and 3α-Hydroxysteroid Dehydrogenases: Key Enzymes in Androgen Metabolism

115 citations , March 2001 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism”

This article reviews how different 5alpha-reductase and 3alpha-HSD enzymes impact androgen levels and highlights their potential as drug targets for androgen-related diseases, but provides no new experimental findings.